190 related articles for article (PubMed ID: 35815437)
1. A versatile design platform for glycoengineering therapeutic antibodies.
Ludwig SD; Bernstein ZJ; Agatemor C; Dammen-Brower K; Ruffolo J; Rosas JM; Post JD; Cole RN; Yarema KJ; Spangler JB
MAbs; 2022; 14(1):2095704. PubMed ID: 35815437
[TBL] [Abstract][Full Text] [Related]
2. Chemoenzymatic glycoengineering of intact IgG antibodies for gain of functions.
Huang W; Giddens J; Fan SQ; Toonstra C; Wang LX
J Am Chem Soc; 2012 Jul; 134(29):12308-18. PubMed ID: 22747414
[TBL] [Abstract][Full Text] [Related]
3. Modulating antibody effector functions by Fc glycoengineering.
García-Alija M; van Moer B; Sastre DE; Azzam T; Du JJ; Trastoy B; Callewaert N; Sundberg EJ; Guerin ME
Biotechnol Adv; 2023 Oct; 67():108201. PubMed ID: 37336296
[TBL] [Abstract][Full Text] [Related]
4. A Detailed Protocol for Generation of Therapeutic Antibodies with Galactosylated Glycovariants at Laboratory Scale Using In-Vitro Glycoengineering Technology.
Voruganti S; Xu J; Li X; Balakrishnan G; Singh SM; Kar SR; Das TK
J Pharm Sci; 2021 Feb; 110(2):935-945. PubMed ID: 33039440
[TBL] [Abstract][Full Text] [Related]
5. Glycosylation engineering of therapeutic IgG antibodies: challenges for the safety, functionality and efficacy.
Mimura Y; Katoh T; Saldova R; O'Flaherty R; Izumi T; Mimura-Kimura Y; Utsunomiya T; Mizukami Y; Yamamoto K; Matsumoto T; Rudd PM
Protein Cell; 2018 Jan; 9(1):47-62. PubMed ID: 28597152
[TBL] [Abstract][Full Text] [Related]
6. The interplay of protein engineering and glycoengineering to fine-tune antibody glycosylation and its impact on effector functions.
Wang Q; Wang T; Zhang R; Yang S; McFarland KS; Chung CY; Jia H; Wang LX; Cipollo JF; Betenbaugh MJ
Biotechnol Bioeng; 2022 Jan; 119(1):102-117. PubMed ID: 34647616
[TBL] [Abstract][Full Text] [Related]
7. Homogeneous Antibody-Drug Conjugates via Glycoengineering.
Tang F; Shi W; Huang W
Methods Mol Biol; 2019; 2033():221-238. PubMed ID: 31332757
[TBL] [Abstract][Full Text] [Related]
8. Influence of N-glycosylation on effector functions and thermal stability of glycoengineered IgG1 monoclonal antibody with homogeneous glycoforms.
Wada R; Matsui M; Kawasaki N
MAbs; 2019; 11(2):350-372. PubMed ID: 30466347
[TBL] [Abstract][Full Text] [Related]
9. Multi-Angle Effector Function Analysis of Human Monoclonal IgG Glycovariants.
Dashivets T; Thomann M; Rueger P; Knaupp A; Buchner J; Schlothauer T
PLoS One; 2015; 10(12):e0143520. PubMed ID: 26657484
[TBL] [Abstract][Full Text] [Related]
10. Implementation of in vitro glycoengineering of monoclonal antibodies into downstream processing of industrial production.
Malik S; Grunert I; von Roman MF; Walch H; Dams T; Thomann M; Falkenstein R
Glycobiology; 2022 Mar; 32(2):123-135. PubMed ID: 34939096
[TBL] [Abstract][Full Text] [Related]
11. Glycosylation of IgG-Fc: a molecular perspective.
Kiyoshi M; Tsumoto K; Ishii-Watabe A; Caaveiro JMM
Int Immunol; 2017 Jul; 29(7):311-317. PubMed ID: 28655198
[TBL] [Abstract][Full Text] [Related]
12. Sculpting therapeutic monoclonal antibody N-glycans using endoglycosidases.
Trastoy B; Du JJ; García-Alija M; Li C; Klontz EH; Wang LX; Sundberg EJ; Guerin ME
Curr Opin Struct Biol; 2022 Feb; 72():248-259. PubMed ID: 34998123
[TBL] [Abstract][Full Text] [Related]
13. Generation of site-distinct N-glycan variants for in vitro bioactivity testing.
Brühlmann D; Vuillemin T; Satwekar A; Galano E; Palmese A; D'Angelo A; Manco Z; Souquet J; Broly H; Sauer M; Hemberger J; Jordan M
Biotechnol Bioeng; 2019 May; 116(5):1017-1028. PubMed ID: 30659587
[TBL] [Abstract][Full Text] [Related]
14. Glycoengineering of Antibodies for Modulating Functions.
Wang LX; Tong X; Li C; Giddens JP; Li T
Annu Rev Biochem; 2019 Jun; 88():433-459. PubMed ID: 30917003
[TBL] [Abstract][Full Text] [Related]
15. Sialylation as an Important Regulator of Antibody Function.
Vattepu R; Sneed SL; Anthony RM
Front Immunol; 2022; 13():818736. PubMed ID: 35464485
[TBL] [Abstract][Full Text] [Related]
16. In vitro glycoengineering of IgG1 and its effect on Fc receptor binding and ADCC activity.
Thomann M; Schlothauer T; Dashivets T; Malik S; Avenal C; Bulau P; Rüger P; Reusch D
PLoS One; 2015; 10(8):e0134949. PubMed ID: 26266936
[TBL] [Abstract][Full Text] [Related]
17. N-Glycosylation Design and Control of Therapeutic Monoclonal Antibodies.
Sha S; Agarabi C; Brorson K; Lee DY; Yoon S
Trends Biotechnol; 2016 Oct; 34(10):835-846. PubMed ID: 27016033
[TBL] [Abstract][Full Text] [Related]
18. Glycosylation of Plant-Produced Immunoglobulins.
Göritzer K; Strasser R
Exp Suppl; 2021; 112():519-543. PubMed ID: 34687021
[TBL] [Abstract][Full Text] [Related]
19. Impact of N-Linked Glycosylation on Therapeutic Proteins.
Chen B; Liu W; Li Y; Ma B; Shang S; Tan Z
Molecules; 2022 Dec; 27(24):. PubMed ID: 36557993
[TBL] [Abstract][Full Text] [Related]
20. Importance and Monitoring of Therapeutic Immunoglobulin G Glycosylation.
Mimura Y; Saldova R; Mimura-Kimura Y; Rudd PM; Jefferis R
Exp Suppl; 2021; 112():481-517. PubMed ID: 34687020
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
